I mplantable cardioverter defibrillators (ICDs) in children and patients with congenital heart disease (CHD) can be lifesaving. 1 Pediatric ICD patients and adults with CHD represent unique subsets of patients undergoing ICD implantation. 2, 3 Children and CHD patients of all ages with ICDs face issues related to increased likelihood of nonstandard device/ lead implantation strategies and the need for multiple procedures over a lifetime. Size constraints because of body habitus and abnormal venous and intracardiac anatomy of patients with CHD may preclude transvenous lead placement. Through growth and development, pediatric patients can anticipate decades of device therapy. The current limitations of lead durability and battery longevity guarantee that these patients will require multiple generator changes and possible lead revisions/extractions. 2 Previous pediatric and congenital retrospective studies have been heterogeneous series with limited capability to extrapolate the findings to a broader ICD population. [4] [5] [6] [7] [8] [9] [10] The European experience with ICDs in adults with CHD is described elsewhere. 11 proportion of ICD implants for primary prevention and secondary prevention indications, the distribution of transvenous and nontransvenous lead implantations, and to determine the prevalence of CRT-D in these populations.
Methods
The ICD Registry gathers data on ICD/CRT-D generators and leads (including atrial, ventricular, defibrillator, left-heart, and other leads) at time of implant, revision, replacement, or abandonment. The V2.1 data form contains pediatric and CHD-specific data entry including age at procedure, presence of particular forms of CHD, and lead characteristics. The Center for Medicare and Medicaid Services has mandated since 2006 collection of data in the NCDR-ICD Registry as a stipulation of payment for all ICD implantations in the United States covered by Medicare. Although non-Center for Medicare and Medicaid Services covered implants were not required to be entered, a majority of the participating hospitals enter all implantation data such that ≈90% of all US ICD implants are reflected in the registry. A steering committee of the NCDR/American College of Cardiology prospectively defined all variables with details at www.ncdr.com/ WebNCDR/icd/resources/documentsv2. This report describes all ICD procedures for patients with CHD or <21 years of age in the registry data V2.1 between April 2010 and December 2012 ( Figure 1 ). This analysis includes 4614 ICD procedures in 4527 unique patients from 900 facilities in comparison with the total registry enrollees (421 182 ICD procedures for 414 718 patients from 1588 facilities) during the same time period. There are 3139 ICD procedures for patients with CHD occurring at 762 separate facilities and 1601 ICD procedures for pediatric patients from 520 facilities. There are 126 procedures performed in pediatric patients with CHD ( Figure 1 ).
Variables of interest included ICD implant indications (primary versus secondary prevention), lead implantation routes (transvenous versus nontransvenous), New York Heart Association class, and whether a pediatric cardiologist performed the procedure. Patients with CHD included all registry patients with a diagnosis of any of the following: atrial septal defect, ventricular septal defect, tetralogy of Fallot, transposition of the great vessels (TGVs), Ebstein anomaly, or common ventricle (CV). As a separate group of interest from the CHD cohort, patients with structural abnormalities including hypertrophic cardiomyopathy, left ventricular (LV) noncompaction, LV aneurysm, arrhythmogenic right ventricular dysplasia, and giant cell myocarditis were examined. Primary electrical disorders (long QT syndrome, Brugada syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia [VT], and idiopathic VT/ ventricular fibrillation [VF]) were also examined. We also report on pediatric intra-and postprocedure events.
The NCDR defines primary prevention as an indication for an ICD to prevent sudden cardiac death and refers to the use of ICDs in individuals who are at risk for but have not yet had an episode of sustained VT, VF, or resuscitated cardiac arrest. Secondary prevention refers to an indication for ICD exclusively for patients who have survived ≥1 cardiac arrests or sustained VT/VF. Patients with cardiac conditions associated with a high risk of sudden death who have unexplained syncope that is likely because of ventricular arrhythmias are considered to have a secondary indication.
Lead route for nontransvenous leads included LV epicardial lead location and subcutaneous array. Possible lead locations on V2.1 data entry form included right atrial endocardial, LV epicardial, RV endocardial, superior vena cava/subclavian, LV via coronary venous sinus, subcutaneous array, or other.
Statistical Analysis
We compared ICD procedure types and indications (primary versus secondary prevention versus unknown) and lead routes (transvenous versus nontransvenous leads) for the corresponding cohorts. Univariate associations were examined using t testing or F test for continuous variables and χ 2 test for categorical variables. Missing values are rare (<1%) for selected variables in this analysis and are imputed as median of nonmissing values for continuous variables and the most common category for categorical variables. P values <0.05 were considered statistically significant.
All analyses were done at the Yale Center for Outcomes Research and Evaluation with SAS version 9.3 (SAS Institute, Cary, NC).
Results

Demographics
During the 33-month study period, there were 3139 procedures for patients with CHD, 1601 for patients <21 years, and 126 for patients with CHD <21 years of age ( Figure 1 ). Tables 1 and  2 show CHD and pediatric patient demographics, respectively. Figure 2A and 2B shows the distribution of congenital and structural defects in the cohort of pediatric and CHD patients.
Implant Patient Characteristics
Primary Versus Secondary Prevention ICD indications among patients with CHD were primary prevention in 1943 (61.9%) and secondary prevention in 1107 (35.2%) procedures. Tetralogy of Fallot (n=379; 50.5%) and CV (n=13; 52.0%) patients had the highest proportion of secondary prevention devices ( Figure 3A ). Among pediatric patients with primary electric disorders, catecholaminergic polymorphic VT (n=18; 85.7%) and idiopathic primary VT/ VF (n=35; 63.6%) patients had the highest rates of secondary prevention, followed by long QT syndrome (n=138; 56.6%), Brugada syndrome (n=18; 41.9%), and short QT syndrome (n=1; 20.0%). Pediatric patients had 935 (58.4%) primary prevention and 588 (36.7%) secondary prevention devices.
VT/Cardiac Arrests
Among the cohort of CHD or pediatric patients, there were 2097 ICD procedures associated with spontaneous VT Figure 1 . Congenital heart disease (CHD) and pediatric Implantable Cardioverter Defibrillator (ICD) Registry populations for this report. All patients with a CHD diagnosis, as well as any patient <21 years of age undergoing an ICD procedure between April 2010 and December 2012 from the registry were included. December 2014 occurring anytime between birth and time of first ICD generator procedure (primary prevention, 42.7%; secondary prevention, 54.7%) and 784 with hemodynamic instability (primary prevention, 24.1%; secondary prevention, 73.9%). Among 794 cardiac arrests, 702 were VT/VF arrests (primary prevention, 8.0%; secondary prevention, 90.2%) and 33 were bradycardic Among the entire cohort of CHD or pediatric patients, there were 3436 procedures in which ≥1 new lead was implanted. Lead locations included right atrial endocardial (n=1699), LV epicardial (n=99), RV endocardial (n=3033), superior vena cava/subclavian (n=14), LV via coronary venous system (n=732), subcutaneous array (n=39), and other location (n=90). Patients with transposition of the great vessels (16.1%; P<0.01) and CV (3.6%; P≤0.01) made up significantly more of the nontransvenous lead implantation population than the transvenous population (TGV, 7.9%; CV, 0.4%). The median age of registry TGV patients with transvenous leads (n=354) was 38 years (25th-75th percentile range, 29-46 years; 1st percentile, 11 years; 99th percentile, 73 years), whereas the nontransvenous TGV patient (n=22) median age was 33.5 years (25th-75th percentile range, 25-42 years; 1st percentile, <12 months; 99th percentile, 64 years). Conversely, fewer tetralogy of Fallot patients were in the nontransvenous group (8.0%; P=0.02) compared with transvenous group (16.5%).
Failure to successfully defibrillate during defibrillation threshold testing was significantly higher in the nontransvenous group (n=5; 3.65%) compared with that in the transvenous group (n=10; 0.22%; P=0.001).
Cardiac Resynchronization Therapy Defibrillators
There were 118 CRT-D devices in the cohort of CHD or pediatric patients. Among CRT-D procedures, 1072 procedures were indicated for primary prevention (81.3%) and 246 (18.7%) were secondary prevention. There were 1258 procedures characterized as transvenous lead devices (95.4%) and 60 procedures (4.6%) with nontransvenous lead(s) implanted. There were 235 CRT-D devices in pediatric patients and 32 CRT-D in the pediatric group undergoing nontransvenous lead. In the CHD group, there were 1098 CRT-D devices with 881 for primary prevention and 217 devices for secondary prevention.
Primary Electric Disorders
Among the cohort of CHD or pediatric patients, there were 721 procedures in patients with a special syndrome increasing the risk of sudden death including long QT syndrome (n=316), short QT syndrome (n=10), Brugada syndrome (n=47), catecholaminergic polymorphic VT (n=23), idiopathic primary VT/VF (n=120), and other unspecified diagnoses (n=203).
New York Heart Association Class
CHD or pediatric patients undergoing device implantation for primary prevention had higher New York Heart Association classes than secondary prevention patients (P<0.01; Figure 4A and 4B) .
Intra-and Postprocedure Events
There were a total of 52 events reported for patients <21 years. Lead dislodgement (n=18), cardiac arrest (n=14), pneumothorax (n=6), and cardiac tamponade (n=4) had the highest incidences among patients <21 years. Patients with CHD experienced a total of 72 events. Lead dislodgement (n=26), hematoma requiring reoperation/evacuation (n=16), pneumothorax (n=12), and cardiac arrest (n=7) had the highest incidences among patients with CHD.
Pediatric Cardiology Providers
Board-certified pediatric cardiologists performed 187 (4.1%) ICD procedures in the CHD or pediatric patients and 153 procedures in pediatric patients (9.6% of the <21 years of age group).
Discussion
The current analysis represents the largest pooled assessment for CHD and pediatric ICD populations and provides insights into these populations.
A majority (61%) of CHD or pediatric patients receiving ICD therapy had primary prevention devices implanted. This reflects the national trend with increasing primary prevention compared with secondary prevention devices since the 1990s. 10, 12, 13 Tetralogy of Fallot and CV were specific CHD lesions for which a majority had secondary prevention indications. Tetralogy of Fallot carries an increased risk of ventricular tachyarrhythmias and sudden cardiac death. 14 Among pediatric patients with primary electric disorders, catecholaminergic polymorphic VT and idiopathic VT/VF had higher rates of secondary prevention devices. There was a history of VT/VF arrest in 55 patients with a primary prevention device; 37 of whom underwent an initial implant with 20 of the arrests occurring >2 weeks before the procedure. The possibility for error in data entry arises in any registry database and reflects a limitation of the methodology. The NCDR ensures data accuracy through ongoing review and evaluation of participating institutions.
CRT-D implants represented 29% of all devices in these populations. A majority of CRT-D procedures were indicated for primary prevention with limited CRT procedures performed in CHD or pediatric patients. Increased use of CRT-D therapy in CHD and pediatric registry patients is necessary to confirm or refute previously reported benefits of improved ejection fraction and reduced New York Heart Association scores after CRT in the CHD population and should be studied prospectively. 9 These data suggest that CRT-D devices may be underutilized in the pediatric and congenital populations.
It is thought that there is increased use of nonstandard lead implantation routes for CHD and pediatric patients because of smaller body habitus and contraindications to transvenous implantation such as mechanical tricuspid valve, venous obstruction, anomalous venous connections, endocarditis, or residual intracardiac shunts. 15 Younger age and decreased stature of patients undergoing nontransvenous implantation route as well as over-representation of the TGV and CV patients in the nontransvenous group confirm these expectations. The registry does not collect data on type of surgical repair (atrial versus arterial switch, for example, in TGV), associated anomalies, or specific contraindications to transvenous lead implantation. Higher rates of nontransvenous leads in TGV is likely an effect of difference in age distribution or surgical technique between the transvenous and nontransvenous TGV patients or may reflect ≥1 of the unmeasured variables mentioned above. Although the difference is statistically significant when considering lead implantation route in TGV and single ventricle patients, the absolute difference from the registry data is minimal. Furthermore, patient weights and total number of nontransvenous implantation leads across all CHD and pediatric patients did not differ from the rates observed in registry adults with structurally normal hearts. This reflects the relative abundance of simple and moderate complexity CHD (atrial septal defect, ventricular septal defect, tetralogy of Fallot, and Ebstein), as well as the diagnosis of congenital arrhythmias beyond the first decade of life when these patients are more amenable to the standard transvenous approach. In addition, the youngest patients and those with complex CHD may be implanted at children's hospitals and pediatric centers not necessarily participating in the ICD Registry and therefore are unfortunately not fully accounted for in the present analyses. A single center retrospective pediatric/congenital institutional review found a rate of 16% nontransvenous lead placement, for example. 16 Selection bias at the pediatric academic centers almost certainly plays a role in shaping these impressions, as the registry shows that even among the CHD and pediatric patients in the present cohort, a board-certified pediatric cardiologist was only involved in 4% of the total study population cases. Along similar lines, the low reported rates of intra-and postprocedural events in pediatric and CHD patients confirms the safety of the ICD implantation in these populations at participating centers. Furthermore, whether participating NCDR hospitals include all their pediatric cases in the registry data is not known. Wider participation in the ICD Registry from pediatric cardiologists is desirable to accurately measure quality and outcomes of care in pediatric and CHD patients receiving ICD therapy. The incorporation of refined pediatric and CHD patient data in the updated ICD Registry enables pediatric electrophysiologists to review pediatric and CHD-associated ICD characteristics across hundreds of centers throughout the United States. Indications for appropriate use of ICD therapy in CHD and pediatric patients are based on expert consensus with single center data and retrospective studies. The ICD Registry provides critically needed benchmarking and quality data to those caring for children and adults with CHD.
Conclusions
The NCDR-ICD Registry improves national surveillance of pediatric and CHD patients requiring ICD therapy. Registry data for 2010 to 2012 demonstrates primary prevention device indications similar to the national trend of increasing primary prevention implantations. Patients undergoing ICD procedures for primary prevention have higher New York Heart Association scores and lower ejection fractions compared with the secondary prevention group with higher rates of cardiac arrest and VT. Younger and shorter stature patients along with more complex forms of CHD underwent nontransvenous lead implantation at higher rates than the overall cohort and in comparison with the entire registry. Greater participation from pediatric cardiologists will improve the NCDR's ability to enhance understanding of the appropriate timing and indications for ICD therapy in this important and growing population.
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CLINICAL PERSPECTIVE
Pediatric and congenital heart disease (CHD) patients requiring implantable cardioverter defibrillator therapy present unique long-term management and anatomic issues. In 2010, the National Cardiovascular Data Registry expanded data collection for variables of specific interest to providers caring for these populations. This report describes the implant characteristics of the largest pooled cohort of pediatric and CHD patients to date. In keeping with national trends during the past 2 decades, we found rates of primary prevention exceed secondary prevention for both pediatric and CHD patients. New York Heart Association class is higher for primary versus secondary prevention patients. Although younger and shorter patients have higher rates of nontransvenous lead implantation, the overall rates of transvenous versus nontransvenous lead implantation do not differ from the overall registry rates. Board-certified pediatric cardiologists implant only a small percentage of the devices for this cohort, suggesting selection bias in favor of over-representation of less complex CHD patients in this cohort. Enhanced participation from academic children's medical centers and centers of excellence in adult CHD nationwide will provide greater understanding of the myriad management issues arising within these special populations.
